Floatz logo

N-ETHYL-4-(2-(4-FLUORO-2,6-DIMETHYLPHENOXY)-5-(2-HYDROXYPROPAN-2-YL)PHENYL)-6-METHYL-7-OXO-6,7-DIHYDRO-1H-PYRROLO(2,3-C)PYRIDINE-2-CARBOXAMIDE

Acute Myeloid Leukemia (AML)

AbbVieSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

685 Active assets in the Acute Myeloid Leukemia (AML) cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →